A video and article about 3-D printing and how it's being used in medicine.
What’s the real story on saturated fat? Can you eat red meat and butter again? WebMD tells you what you need to know.
They won't take steps to reach a healthy weight if they don't see the problem, experts note
Threat of respiratory disease may be up to 30 percent higher, study suggests
Obamacare Court Decisions: FAQ
WASHINGTON (AP) — In rapid succession, six federal judges on two appeals courts weighed in on a key component of President Barack Obama's health care law. Their votes lined up precisely with the party of the president who appointed them.
A key selling point of the drug known as Dabigatran or Pradaxa was that it required no blood-level monitoring, as does competitor warfarin. Dabigatran's maker, Boehringer Ingelheim, had said the drug was better than warfarin at reducing stroke in people with irregular heart rhythm, with a similar risk of major bleeds, according to the British Medical Journal (BMJ). Based on its own probe, the journal accused Boehringer of concealing information that blood-level monitoring could in fact reduce major bleeds by up to 30-40 percent compared to warfarin. According to BMJ investigations editor Deborah Cohen, who conducted the research, millions of people take the anti-clotting drug, with blood levels found to vary greatly between patients.